The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.
Christoph Rochlitz
Honoraria - Roche
Roger von Moos
No relevant relationships to disclose
Martin Bigler
No relevant relationships to disclose
Khalil Zaman
No relevant relationships to disclose
Sandro Anchisi
Consultant or Advisory Role - Roche
Marc Küng
No relevant relationships to disclose
Kyung Jae Na
No relevant relationships to disclose
Daniela Baertschi
No relevant relationships to disclose
Markus M. Borner
No relevant relationships to disclose
Tamara Rordorf
No relevant relationships to disclose
Daniel Rauch
No relevant relationships to disclose
Andreas Mueller
No relevant relationships to disclose
Thomas Ruhstaller
No relevant relationships to disclose
Marcus Vetter
Honoraria - Roche
Juerg Bernhard
No relevant relationships to disclose
Andreas Trojan
No relevant relationships to disclose
Ursula Hasler-Strub
No relevant relationships to disclose
Richard Cathomas
No relevant relationships to disclose
Ralph C. Winterhalder
No relevant relationships to disclose